Skip to main content
Fig. 5 | Allergy, Asthma & Clinical Immunology

Fig. 5

From: Post hoc analysis examining symptom severity reduction and symptom absence during food challenges in individuals who underwent oral immunotherapy for peanut allergy: results from three trials

Fig. 5

Participants Asymptomatic at All Peanut Protein Doses  ≤ 1000 mg in the Exit DBPCFC. A In randomized, controlled trials. B In the open-label, follow-on trial. Freedom from symptoms up to 1000 mg of peanut protein. Freedom from symptoms indicated participants were asymptomatic to peanut exposure during the entire DBPCFC. aRR (PTAH vs placebo) for any symptoms in the intention-to-treat population. CI confidence interval, DBPCFC double-blind, placebo-controlled food challenge, PTAH peanut (Arachis hypogaea) allergen powder-dnfp, RR relative risk

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us